Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 459 Cr.
- Current Price ₹ 294
- High / Low ₹ 392 / 178
- Stock P/E 58.5
- Book Value ₹ 70.2
- Dividend Yield 0.00 %
- ROCE 15.5 %
- ROE 9.33 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 61.2 to 79.1 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 39 | 71 | 99 | 114 | 136 | 156 | |
| 36 | 66 | 89 | 98 | 117 | 139 | |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 16 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 11% |
| 1 | 1 | 1 | 1 | 2 | 2 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% |
| 1 | 3 | 7 | 10 | 12 | 8 | |
| EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 | 5.23 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 16% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 56% |
| 3 Years: | 9% |
| TTM: | -31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 24% |
| 3 Years: | 20% |
| Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 |
| 9 | 11 | 23 | 29 | 11 | 0 | |
| 9 | 17 | 23 | 19 | 15 | 89 | |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 |
| 4 | 5 | 4 | 19 | 20 | 24 | |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 |
| 18 | 26 | 46 | 52 | 66 | 144 | |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 3 | 7 | 12 | 9 | -13 | -29 | |
| -1 | -5 | -7 | -5 | -4 | -27 | |
| -1 | -1 | -2 | -3 | 23 | 79 | |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 |
| Working Capital Days | 76 | 36 | 58 | 89 | 105 | 97 |
| ROCE % | 32% | 38% | 36% | 28% | 16% |
Documents
Announcements
-
Outcome of Board Meeting
28 May 2025 - Approved audited FY25 standalone and consolidated financial results; appointed internal auditor; no IPO fund deviation.
-
Board Meeting Intimation
22 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Board Meeting Intimation
22 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 28-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Board Meeting Intimation
10 May 2025 - INFINIUM PHARMACHEM LIMITED has informed about Board Meeting to be held on 23-May-2025 to consider and approve the Yearly Audited Financial results of the Company …
-
Price movement
25 April 2025 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …
Annual reports
Concalls
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis